|Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia|
JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ...
Blood 109 (2), 399-404, 2007
|Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease|
TS Lin, AS Ruppert, AJ Johnson, B Fischer, NA Heerema, LA Andritsos, ...
Journal of Clinical Oncology 27 (35), 6012, 2009
|Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers|
T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ...
Journal of clinical oncology 29 (17), 2357, 2011
|miR-221 silencing blocks hepatocellular carcinoma and promotes survival|
JK Park, T Kogure, GJ Nuovo, J Jiang, L He, JH Kim, MA Phelps, ...
Cancer research 71 (24), 7608-7616, 2011
|Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats|
W Gao, PJ Reiser, CC Coss, MA Phelps, JD Kearbey, DD Miller, ...
Endocrinology 146 (11), 4887-4897, 2005
|Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry|
Z Wu, W Gao, MA Phelps, D Wu, DD Miller, JT Dalton
Analytical chemistry 76 (3), 839-847, 2004
|Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia|
MA Phelps, TS Lin, AJ Johnson, E Hurh, DM Rozewski, KL Farley, D Wu, ...
Blood, The Journal of the American Society of Hematology 113 (12), 2637-2645, 2009
|Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others|
JP Kitzmiller, DK Groen, MA Phelps, W Sadee
Cleveland Clinic journal of medicine 78 (4), 243, 2011
|REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer|
C Comins, J Spicer, A Protheroe, V Roulstone, K Twigger, CM White, ...
Clinical cancer research 16 (22), 5564-5572, 2010
|Discovery and mechanism of highly efficient cyclic cell-penetrating peptides|
Z Qian, A Martyna, RL Hard, J Wang, G Appiah-Kubi, C Coss, MA Phelps, ...
Biochemistry 55 (18), 2601-2612, 2016
|Dose escalation of lenalidomide in relapsed or refractory acute leukemias|
W Blum, RB Klisovic, H Becker, X Yang, DM Rozewski, MA Phelps, ...
Journal of clinical oncology 28 (33), 4919, 2010
|Modeling of active transport systems|
EY Zhang, MA Phelps, C Cheng, S Ekins, PW Swaan
Advanced drug delivery reviews 54 (3), 329-354, 2002
|Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2)|
EY Zhang, MA Phelps, A Banerjee, CM Khantwal, C Chang, F Helsper, ...
Biochemistry 43 (36), 11380-11392, 2004
|Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines|
MA Bill, C Nicholas, TA Mace, JP Etter, C Li, EB Schwartz, JR Fuchs, ...
PloS one 7 (8), e40724, 2012
|Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide–CCI-779 interaction via P-glycoprotein|
CC Hofmeister, X Yang, F Pichiorri, P Chen, DM Rozewski, AJ Johnson, ...
Journal of clinical oncology 29 (25), 3427, 2011
|Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells|
X Zhu, M Badawi, S Pomeroy, DS Sutaria, Z Xie, A Baek, J Jiang, ...
Journal of Extracellular Vesicles 6 (1), 1324730, 2017
|Discovery of anticancer agents of diverse natural origin|
AD Kinghorn, EJC De Blanco, DM Lucas, HL Rakotondraibe, J Orjala, ...
Anticancer research 36 (11), 5623-5637, 2016
|Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples|
GJ Nuovo, M Garofalo, N Valeri, V Roulstone, S Volinia, DE Cohn, ...
Modern Pathology 25 (10), 1333-1344, 2012
|Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition|
W Ni, J Ji, Z Dai, A Papp, AJ Johnson, S Ahn, KL Farley, TS Lin, JT Dalton, ...
PLoS One 5 (11), e13792, 2010
|Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study|
R Molokie, D Lavelle, M Gowhari, M Pacini, L Krauz, J Hassan, V Ibanez, ...
PLoS medicine 14 (9), e1002382, 2017